Image courtesy of Abbott

Abbott Receives FDA Emergency use Authorization and Launches Test to Detect Novel Coronavirus

Originally posted on Abbott.com

– The test will be used on the company’s m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S.

– Abbott shipping 150,000 laboratory tests immediately; tests already sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington

– Company scaling up production at its U.S. manufacturing location to reach capacity for 1 million tests per week by end of March

Abbott announced today that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company’s molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are used on the company’s m2000™ RealTime System. Abbott will be working with health systems and government authorities to deploy additional m2000 systems where they are needed.

“A global challenge like coronavirus requires the commitment and cooperation of everyone who has the ability to help address it,” said Miles D. White, chairman and chief executive officer, Abbott. “I’m proud of the Abbott team and what they’ve accomplished in such a short period of time, and I want to thank the Administration and the FDA for their partnership in making this happen.”

Accelerating testing to help combat the pandemic
As a leader in diagnostics testing, Abbott is working to do its part to combat this global pandemic. Across the U.S., more than 175 m2000 systems are used in hospital and reference laboratories. The systems have the ability to run high volumes of up to 470 tests in 24 hours, helping to meet the increasing demand for testing. Many of these instruments are used in university and community hospitals where patients come for care, resulting in testing that happens closer to the patient rather than sending it to an offsite lab. Abbott is immediately distributing 150,000 tests and will continue ramping up production to the highest levels possible, with the goal of providing up to 1 million tests per week. Abbott is manufacturing these tests in the U.S.

 

Latest News

Syracuse University campus

News Roundup: TV Diversity, Syracuse Hire, and Segregated Training

Check out our news roundup of diversity and inclusion updates and insights from across the U.S.: Syracuse University Creates Athletics Diversity Position  While most colleges and universities around the county are making COVID-19-related cuts in regard to their athletic departments, Syracuse University has hired Salatha T. Willis as the associate athletic…

Cesar Conde

NBCUniversal Sets Ambitious 50% Diversity Goal for Women, People of Color

Cesar Conde, chairman at NBCUniversal News Group, announced a groundbreaking goal to have a 50% diverse workforce at NBCUniversal, according to Deadline. Conde, the first Latino in this role, outlined his plans in an internal video for employees on Wednesday. The ultimate goal is for NBCUniversal, No. 7 on DiversityInc’s 2020…

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries

Originally published on jnj.com. Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic In 2020, the initiative aims to reach at least 125,000 patients and could…

Toyota, Alabama A&M and Huntsville Hospital Collaborate to Make COVID-19 Testing Easier

Originally published on pressroom.toyota.com. $100,000 grant provides free service to the community Alabama A & M University (AAMU), Huntsville Hospital and Toyota are developing a mobile health clinic initiative to provide free COVID-19 testing to underserved communities in Madison County. Launching later this year, the mobile medical clinic program has…

Sanofi and Regeneron Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Originally published on sanofi.com. Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo)….

TD Bank: How a PPP Loan Saved Essential Jobs for Hundreds of Frontline Healthcare Heroes Amid COVID-19

Originally published on newscenter.td.com. Yet, “it’s not about earning a paycheck” for these medical responders A hero is defined as “a person who is admired or idealized for courage, outstanding achievements or noble qualities.” Never has that word resonated more than right now, with millions of frontline responders risking their…

Boeing Dreamlifter Transports 500,000 Protective Face Masks for Utah Students and Teachers

Originally published on boeing.mediaroom.com. Partnered with the state of Utah, Atlas Air, H.M. Cole, Cotopaxi, Flexport and UPS to deliver face masks to school districts with the greatest need Boeing [NYSE: BA] today completed its 12th COVID-19 transport mission, using a Boeing Dreamlifter to bring personal protective equipment (PPE) to the United…